For example, a study performing high-fidelity CRISPR-based engineering found that KRAS (G12D) is sensitive to EGFR inhibition in pancreatic cancer models, while KRAS (G12C) mutants selectively respond only to covalent G12C inhibitors when EGFR is inhibited69. This evidence concerns the gene KRAS and familial pancreatic carcinoma.